Association of SFRP1 gene C>T(rs3242) polymorphism in Breast cancer patients
International Journal of Drug Delivery Technology · 29.05.2026 · 16 (37s)
DOI: 10.25258/ijddt.16.37s.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 29.05.2026. Verfasst von Sarika Jarjapu und 4 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Breast cancer is second leading cancer in India with rising incidence and mortality posing a significant health burden. It arises from molecular dysregulation of key pathways regulating cell growth, differentiation, and migration. Among these, aberrant activation of the Wnt signalling pathway plays a central role in tumor initiation, progression, and metastasis. The Wnt signaling system is a critical pathway that regulates embryonic development and adult homeostasis. Secreted frizzled-related proteins (SFRPs) are extracellular inhibitors of Wnt signaling that act by binding directly to Wnt ligands or Frizzled receptors. SFRPs can act as anti-Wnt agents and suppress cancer growth by blocking the action of Wnt ligands. However, SFRPs are often silenced by promoter methylation in cancer cells, resulting in hyper activation of the Wnt pathway. Epigenetic modifiers can reverse the silencing and restore SFRPs expression. The potential of SFRPs as a therapeutic target, on tumor development the effects of SFRPs remain unclear. We hypothesize that SFRPs play a significant role in BC progression, and therefore, promising prognostic biomarkers as well as therapeutic targets. Material and Method: The present study was aimed to find association between SFRP1 C>T (rs3242) gene polymorphism and breast cancer development. For this purpose, 503 primary breast cancer patients and 404 healthy aged matched controls were genotyped through PCR-RFLP method. Result: We report for the first time a potential association between the TT genotype of rs3242 SNP in the Wnt antagonist SFRP1 and breast cancer risk.
Zitieren
APA
Jarjapu, S., Meka, P. B., Digumarti, R. R., Satti, V., & Annamaneni, S. (2026). Association of SFRP1 gene C>T(rs3242) polymorphism in Breast cancer patients. International Journal of Drug Delivery Technology, 16(37s). https://doi.org/10.25258/ijddt.16.37s.1
Vancouver
Jarjapu S, Meka PB, Digumarti RR, Satti V, Annamaneni S. Association of SFRP1 gene C>T(rs3242) polymorphism in Breast cancer patients. International Journal of Drug Delivery Technology. 2026;16(37s). doi:10.25258/ijddt.16.37s.1
BibTeX
@article{Jarjapu2026,
author = {Jarjapu, Sarika and Meka, Phani Bhushan and Digumarti, Raghunadha Rao and Satti, Vishnupriya and Annamaneni, Sandhya},
title = {Association of SFRP1 gene C>T(rs3242) polymorphism in Breast cancer patients},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {37s},
doi = {10.25258/ijddt.16.37s.1}
}
EUVIMED